Roche to Acquire 89bio in $3.5B Deal Expanding Liver Disease Portfolio

Published on LinkedIn (via Spencer Knight)

Roche announced a $3.5B acquisition of 89bio, adding pegozafermin, a late-stage therapy for fatty liver disease, to its CVRM pipeline. The deal strengthens Roche’s presence in metabolic and liver disease, with closing expected in Q4 2025.

👉 Read the full article: Roche Makes $3.5B Liver Disease Acquisition

Disclaimer

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link. SSCTR does not provide medical advice, and the views expressed are for educational purposes only.